Featured Press Release

  • Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference
    5/28/19 4:30 pm EDT
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference as follows:   Date: Tuesday, June 4, 2019See More
  • Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference
    5/15/19 4:30 pm EDT
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference as follows: Date:     Wednesday, May 22, 2019See More
  • Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results
    5/7/19 6:50 am EDT

    -- Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of $1.05 per basic and $1.01 per diluted share --

    -- Revised licensing agreement for BENDEKA® extends term of contract and increases royalty rate to 32% in 2021 --

    -- CMS issues unique J-code for BELRAPZO™ (500mL infusion bendamustine solution) –

    -- Announced statistically significant neuroprotective effects of RYANODEX® in a well-established nerve agent model --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced its financial results for the three months ended March 31, 2019. Highlights of, and subsequent to, the first quarter of 2019 include: Business and Recent Highlights: Completed a successful study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium) for the treatment of nerveSee More

Featured Presentation

Business Wire InvestorHQsm